Processa Pharmaceuticals Stock (NASDAQ:PCSA)


ForecastOwnershipFinancialsChart

Previous Close

$0.90

52W Range

$0.90 - $17.40

50D Avg

$1.27

200D Avg

$1.78

Market Cap

$2.97M

Avg Vol (3M)

$65.69K

Beta

0.60

Div Yield

-

PCSA Company Profile


Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Mar 07, 2014

Website

PCSA Performance


PCSA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-22.91M$-27.53M$-12.13M
Net Income$-11.12M$-54.85M$-11.43M
EBITDA$-22.91M$-12.20M$-10.76M
Basic EPS-$-3.58$-0.75
Diluted EPS-$-3.58$-0.75

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 22Mar 31, 23 | 4:14 PM
Q3 22Nov 12, 22 | 8:55 PM
Q2 22Aug 14, 22 | 6:13 AM

Peer Comparison


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
FRTXFresh Tracks Therapeutics, Inc.
IKTInhibikase Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
ACXPAcurx Pharmaceuticals, Inc.
INBXInhibrx Biosciences, Inc.
FENCFennec Pharmaceuticals Inc.
SCPSScopus BioPharma Inc.
AKTXAkari Therapeutics, Plc
ANTXAN2 Therapeutics, Inc.
THRDThird Harmonic Bio, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
CELCCelcuity Inc.
MACKMerrimack Pharmaceuticals, Inc.
ELVNEnliven Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.